Operating CF
$1.36B
Capex
−$269.10M
Free Cash Flow
$1.09B
FCF Margin
+80.2%
Cash flow waterfall for Edwards Lifesciences (EW) — TTM through Q1 2026
Free cash flow: $1.09B
Note: Other Investing is large — driven mainly by purchases or sales of investments.
Cash flow breakdown for Edwards Lifesciences (EW) — TTM through Q1 2026
| Line item | Amount | Running total |
|---|---|---|
| Operating Cash Flow | $1.36B | $1.36B |
| Capital Expenditure | −$269.10M | $1.09B |
| Free Cash Flow | $1.09B | $1.09B |
| Acquisitions | −$35.10M | $1.05B |
| Other Investing | −$586.80M | $467.60M |
| Share Buybacks | −$410.90M | $56.70M |
| Other Financing & FX | −$758.00M | −$701.30M |
| Net Cash Decrease | −$701.30M | −$701.30M |
- Operating Cash Flow$1.36B
- Capital Expenditure−$269.10M
- Free Cash Flow$1.09B
- Acquisitions−$35.10M
- Other Investing−$586.80M
- Share Buybacks−$410.90M
- Other Financing & FX−$758.00M
- Net Cash Decrease−$701.30M
Want to see what drove the FCF change?Free Cash Flow Bridge
Frequently asked questions
Data & methodology
Edwards Lifesciences (EW) Key Financials
Charts, filings, and peer comparison for every metric
Income Statement
Balance Sheet
Cash Flow
Explore more
Deep-dives across the income statement, cash flow, capital return, and valuation
Overview
Income Statement